SEC Tracker
Get the app

Aibotics AIBT

Aibotics Q1 FY26: revenue $0

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Aibotics reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0−100% from $2K in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$418KAgainst −$591K in Q1 FY2510-Q income statement, on EDGAR
  3. Cash and cash equivalents$289K+84% from $157K in Q1 FY2510-Q balance sheet, on EDGAR
  4. Cash from operations−$36KAgainst −$28K in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Aibotics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Agentix AGTX public float $1M, Sep 30, 2025
  2. Galera Therapeutics GRTX public float $2M, Jun 30, 2025
  3. ProtoKinetix PKTX public float $2M, Jun 30, 2026
  4. Evofem Biosciences EVFM public float $1M, Jun 30, 2025
  5. Regen BioPharma RGBP public float $1M, Mar 31, 2025, over 18 months old